12 assets in Myelodysplastic Syndrome With Excess Blasts-1

Therapeutic assets addressing Myelodysplastic Syndrome With Excess Blasts-1, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Myelodysplastic Syndrome With Excess Blasts-1	Masonic Cancer Center, University of Minnesota	P2	B (62)
Thiotepa Myelodysplastic Syndrome With Excess Blasts-1	Fred Hutchinson Cancer Center	P2	B (62)
Busulfanum Myelodysplastic Syndrome With Excess Blasts-1	Fred Hutchinson Cancer Center	P2	B (61)
Fludarabine Myelodysplastic Syndrome With Excess Blasts-1	Masonic Cancer Center, University of Minnesota	P2	B (61)
Tacrolimus Myelodysplastic Syndrome With Excess Blasts-1	Fred Hutchinson Cancer Center	P2	B (61)
Methotrexate Myelodysplastic Syndrome With Excess Blasts-1	Fred Hutchinson Cancer Center	P2	B (59)
Allopurinol Myelodysplastic Syndrome With Excess Blasts-1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Azacitidine Myelodysplastic Syndrome With Excess Blasts-1	National Cancer Institute (NCI)	P2	CCC (53)
Lenalidomide Myelodysplastic Syndrome With Excess Blasts-1	National Cancer Institute (NCI)	P2	CCC (53)
Sirolimus Myelodysplastic Syndrome With Excess Blasts-1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Vorinostat Myelodysplastic Syndrome With Excess Blasts-1	National Cancer Institute (NCI)	P2	CCC (52)
Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4 Myelodysplastic Syndrome With Excess Blasts-1	M.D. Anderson Cancer Center	P1	CC (43)